ArticleLeukemia & lymphoma2014

Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.

Rebecca B Klisovic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.